A randomized controlled trial to evaluate outcomes with Aggrenox in patients with SARS-CoV-2 infection
This study evaluated the effect of these two drugs formulated together asAggrenox in hospitalized COVID-19 patients. MethodsIn an open-label, single site randomized controlled trial (RCT), hospitalized COVID-19 patients were assigned to adjunctive Aggrenox (Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally) with standard of care treatment compared to standard of care treatment alone. Primary endpoint was illness severity according to changes on the eight-point COVID ordinal scale, with levels of 1 to 8 where higher scores represent worse illness. Secondary endpoints included all-cause mortality and respiratory failure. ...
Source: PLoS One - January 30, 2023 Category: Biomedical Science Authors: Amit Singla Source Type: research
Navigating Antiplatelet Treatment Options for Stroke: Evidence-Based and Pragmatic Strategies
AbstractPurpose of ReviewThe benefit of using antiplatelet monotherapy in acute ischemic stroke and secondary stroke prevention is well established. In the last few years, several large randomized trials showed that the use of short-term dual antiplatelet therapy in particular stroke subtypes may reduce the risk of recurrent ischemic events. The aim of this article is to provide a critical analysis of the current evidence and recommendations for the use of antiplatelet agents for stroke prevention.Recent FindingsLong-term therapy with aspirin, clopidogrel, or aspirin plus extended-release dipyridamole is recommended for se...
Source: Current Neurology and Neuroscience Reports - October 13, 2022 Category: Neuroscience Source Type: research
Contemporary antiplatelet therapy for secondary stroke prevention: a narrative review of current literature and guidelines
Stroke Vasc Neurol. 2022 Apr 7:svn-2021-001166. doi: 10.1136/svn-2021-001166. Online ahead of print.ABSTRACTAntiplatelet therapy is one of the mainstays for secondary stroke prevention. This narrative review aimed to highlight the current evidence and recommendations of antiplatelet therapy for stroke prevention.We conducted advanced literature search for antiplatelet therapy. Landmark studies and randomised controlled trials evaluating antiplatelet therapy for secondary stroke prevention are reviewed. Results from Cochrane systematic review, pooled data analysis and meta-analysis are discussed.Single-antiplatelet therapy ...
Source: Atherosclerosis - April 8, 2022 Category: Cardiology Authors: Jay Shah Shimeng Liu Wengui Yu Source Type: research
Contemporary antiplatelet therapy for secondary stroke prevention: a narrative review of current literature and guidelines
Stroke Vasc Neurol. 2022 Apr 7:svn-2021-001166. doi: 10.1136/svn-2021-001166. Online ahead of print.ABSTRACTAntiplatelet therapy is one of the mainstays for secondary stroke prevention. This narrative review aimed to highlight the current evidence and recommendations of antiplatelet therapy for stroke prevention.We conducted advanced literature search for antiplatelet therapy. Landmark studies and randomised controlled trials evaluating antiplatelet therapy for secondary stroke prevention are reviewed. Results from Cochrane systematic review, pooled data analysis and meta-analysis are discussed.Single-antiplatelet therapy ...
Source: Atherosclerosis - April 8, 2022 Category: Cardiology Authors: Jay Shah Shimeng Liu Wengui Yu Source Type: research
Dual Antiplatelet Therapy in Ischemic Stroke Prevention: Which Two Could Be Better than One?
AbstractPurpose of reviewRecurrent stroke after ischemic stroke (IS) or high-risk transient ischemic attack (TIA) increases morbidity and mortality. Secondary stroke prevention strategies include modification of behavioral and vascular risk factors and antithrombotic use, including single or dual antiplatelet therapy (DAPT). In this review, we focus on DAPT indications, combinations, and treatment duration.Recent findingsStudies showed that for patients with mild to moderate non-cardioembolic strokes or those with symptomatic intracranial or mild extracranial stenosis ( ≤ 30% diameter reduction), short-term DAPT (21–...
Source: Current Treatment Options in Neurology - November 5, 2021 Category: Neurology Source Type: research
Preventing Arteriovenous Shunt Failure in Hemodialysis Patients: A Population-Based Cohort Study.
CONCLUSION: Antiplatelet agents but not wafarin might reduce the vascular access thrombosis rate. The gastrointestinal bleeding rate was increased in the group using clopidogrel. Aggrenox should be used with caution in young individuals since it might increase the rate of intracerebral hemorrhage. This article is protected by copyright. All rights reserved.
PMID: 30472783 [PubMed - as supplied by publisher] (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - November 25, 2018 Category: Hematology Authors: Fan PY, Lee CC, Liu SH, Li IJ, Weng CH, Tu KH, Hsieh MY, Kuo CF, Chang TY, Tian YC, Yang CW, Wu HH Tags: J Thromb Haemost Source Type: research
Preventing Arteriovenous Shunt Failure in Hemodialysis Patients: A Population ‐Based Cohort Study
ConclusionAntiplatelet agents but not wafarin might reduce the vascular access thrombosis rate.The gastrointestinal bleeding rate was increased in the group using clopidogrel. Aggrenox should be used with caution in young individuals since it might increase the rate of intracerebral hemorrhage.This article is protected by copyright. All rights reserved. (Source: Journal of Thrombosis and Haemostasis)
Source: Journal of Thrombosis and Haemostasis - November 25, 2018 Category: Hematology Authors: Pei Yi Fan,
Cheng Chia Lee,
Shou Hsuan Liu,
I ‐Jung Li,
Cheng Hao Weng,
Kun Hua Tu,
Mei Yun Hsieh,
Chang Fu Kuo,
Ting‐Yu Chang,
Ya Chung Tian,
Chih Wei Yang,
Hsin Hsu Wu Tags: Original Article ‐ Clinical Haemostasis and Thrombosis Source Type: research
Oral Dipyridamole-Associated Circulatory Collapse
Extended-release dipyridamole plus aspirin is widely used for secondary prevention of ischemic stroke, although the molecular pharmacodynamics of dipyridamole are not completely determined. Adverse effects of fixed-dose combination of aspirin and dipyridamole include headache, bleeding, and gastrointestinal events. Previously, intravenous infusion of dipyridamole in cardiac stress testing has been associated with cardiogenic shock and pulmonary edema. Herein, we report a case study of a 72-year-old man, presented with a transient ischemic attack who suffered a circulatory collapse after an oral dose of 200 mg extended-rele...
Source: Journal of Stroke and Cerebrovascular Diseases - September 2, 2018 Category: Neurology Authors: Pasi Jolma, Jyrki Ollikainen, Ilkka Uurto Source Type: research
O-026 Prior antiplatelet use and thrombectomy outcomes
Conclusion
Prior use of APT drug is associated with higher rates of successful recanalization in ELVO patients after MT, however no difference in rates of sICH or functional outcome was noted. Larger studies are needed to further evaluate the role of prior treatment with APT drug in ELVO patients treated with MT.
Disclosures
A. Pandhi: None. R. Krishnan: None. K. Dillard: None. M. Ishfaq: None. S. Singh: None. D. Hoit: None. A. Arthur: None. G. Tsivgoulis: None. A. Alexandrov: None. L. Elijovich: None. N. Goyal: None. (Source: Journal of NeuroInterventional Surgery)
Source: Journal of NeuroInterventional Surgery - July 23, 2017 Category: Neurosurgery Authors: Pandhi, , Krishnan, R., Dillard, K., Ishfaq, M., Singh, S., Hoit, D., Arthur, A., Tsivgoulis, G., Alexandrov, A., Elijovich, L., Goyal, N. Tags: Oral Abstracts Source Type: research
Antiplatelet Strategies for Secondary Prevention of Stroke and TIA
Abstract
Stroke is a major public health issue, and stroke recurrence accounts for a quarter of all events. Antiplatelet therapy has been extensively studied for secondary stroke prevention and is established as effective in this high-risk population. Several agents have been evaluated in this setting, both in isolation and combination. The most widely used antiplatelet medications are aspirin, clopidogrel, and aspirin plus extended-release dipyridamole. However, new agents and combinations continue to be evaluated. A detailed review of the evidence supporting various antiplatelet regimens for secondary...
Source: Current Atherosclerosis Reports - September 10, 2014 Category: Cardiology Source Type: research
Meta-analysis finds benefit for dual antiplatelet therapy but limitations preclude changing standard mono antiplatelet therapy approach for acute non-cardioembolic ischaemic stroke or transient ischaemic attack
Commentary on: Wong KSL, Wang Y, Leng X, et al.. Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack. An updated systematic review and meta-analysis. Circulation 2013;128:1656–66. Context Current guidelines recommend aspirin, aspirin plus clopidogrel or aspirin plus extended-release dipyridamole for treatment of acute ischaemic stroke (IS) or transient ischaemic attack (TIA) to prevent recurrent stroke, myocardial infarction and cardiovascular death.1 The Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial r...
Source: Evidence-Based Medicine - May 19, 2014 Category: Internal Medicine Authors: Aronow, W. S. Tags: Clinical trials (epidemiology), Epidemiologic studies, Drugs: cardiovascular system, Stroke, Ischaemic heart disease Therapeutics Source Type: research
Spray Drying as a Fast and Simple Technique for the Preparation of Extended Release Dipyridamole (DYP) Microparticles in a Fixed Dose Combination (FDC) Product with Aspirin
Drug Res (Stuttg)DOI: 10.1055/s-0033-1361119© Georg Thieme Verlag KG Stuttgart · New YorkArticle in Thieme eJournals:Table of contents | Full text (Source: Drug Research)
Source: Drug Research - November 18, 2013 Category: Drugs & Pharmacology Authors: Hamishehkar, H.Valizadeh, H.Alasty, P.Monajjemzadeh, F. Tags: Erratum Source Type: research
